Precision medicine—the concept of targeting therapy to a patient’s unique genetic or other relevant characteristics—occupies a prominent place on the national agenda.1 No condition demonstrates recent efforts toward precision medicine more clearly than cancer, and particularly breast cancer. After a decade of molecular subtyping, increasingly comprehensive genomic tests are emerging into breast cancer care. The 21-gene recurrence score (RS) assay has led the way in clinical implementation and thus offers an early opportunity to measure the impact of precision medicine on cancer treatment.
Kurian AW, Friese CR. Precision Medicine in Breast Cancer CareAn Early Glimpse of Impact. JAMA Oncol. 2015;1(8):1109-1110. doi:10.1001/jamaoncol.2015.2719